EIP Pharma Inc
9
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
11.1%
1 terminated/withdrawn out of 9 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
83%
5 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Role: lead
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
Role: lead
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Role: lead
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
Role: lead
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
Role: lead
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
Role: lead
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Role: lead
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
Role: lead
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Role: lead
All 9 trials loaded